# A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

> **NCT04622046** · PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Symptomatic Transthyretin Amyloid Cardiomyopathy

## Interventions

- **DRUG:** ALXN2060

## Key facts

- **NCT ID:** NCT04622046
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2023-11-08
- **Final completion:** 2025-08-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622046, "A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04622046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*